finanzen.net

SCICLONE PHARMACEUTICALS solides Investment

Seite 1 von 1
neuester Beitrag: 03.03.10 14:28
eröffnet am: 08.01.10 13:09 von: macos Anzahl Beiträge: 5
neuester Beitrag: 03.03.10 14:28 von: macos Leser gesamt: 2301
davon Heute: 1
bewertet mit 19 Sternen

08.01.10 13:09
19

2231 Postings, 4093 Tage macosSCICLONE PHARMACEUTICALS solides Investment

Umsatz 2009 ca 75 Mio Dollar  
MK ca 120 Mio Dollar
profitabel EPS von 0,18 - 0,22
Unternehmenspräsentation
http://files.shareholder.com/downloads/SCLN/...resentation_120109.pdf

http://www.sciclone.com/  

11.01.10 13:30
15

2231 Postings, 4093 Tage macosFinancial Update

SciClone Provides 2009 Financial Update
and Initial 2010 Sales Revenue Guidance


-- For 2009, the company anticipates revenues of approximately $72.4 million (unaudited), a 34% increase over 2008.-- Cash, cash equivalents, short and long-term investments are anticipated to be approximately $31.8 million (unaudited) at December 31, 2009, compared with $29.7 million at December 31, 2008.-- The company expects 2010 sales revenue of $82 to $85 million, a 15% increase over 2009

http://finance.yahoo.com/news/...2009-iw-1194964842.html?x=0&.v=1  

12.01.10 14:48
17

2231 Postings, 4093 Tage macosNews

SciClone and Sigma-Tau Announce Positive Preliminary Results in Clinical Study Examining ZADAXIN'S Ability to Enhance Response to H1N1 Vaccine
Study Shows Increase in Seroconversion From 56% to 88% 21 Days After Vaccination

http://finance.yahoo.com/news/...aTau-iw-1790607853.html?x=0&.v=1  

01.02.10 13:01
18

2231 Postings, 4093 Tage macosPerle mit überschaubarem Risiko

TREND INVEST REPORT - SciClone Pharmaceuticals Biotech-Perle
13:11 29.01.10

Kulmbach (aktiencheck.de AG) - Nach Einschätzung der Experten vom "TREND INVEST REPORT" ist die Aktie von SciClone Pharmaceuticals (Profil) eine unentdeckte Biotech-Perle mit überschaubarem Risiko
http://www.ariva.de/news/...Biotech-Perle-TREND-INVEST-REPORT-3228500  

03.03.10 14:28
13

2231 Postings, 4093 Tage macos4Q profit on sales

NEW YORK (AP) -- SciClone Pharmaceuticals Inc. reported a fourth-quarter profit on higher sales of the vaccine booster Zadaxin and lower costs.

The company earned $2.4 million, or 5 cents per share, compared with a loss of $3.1 million, or 7 cents per share, a year earlier. Revenue rose to $18.1 million from $15.3 million.

The results topped the average analyst estimate for a profit of 2 cents per share and revenue of $18 million, according to a survey by Thomson Reuters.

For the full year, SciClone Pharmaceuticals earned $11.9 million, or 25 cents per share, compared with a loss of $8.3 million, or 18 cents per share, in 2008. Revenue rose to $72.4 million from $54.1 million.

Looking ahead, the company expects profit between 31 cents per share and 35 cents per share on revenue between $82 million and $85 million in 2010.

In after-hours trading, shares advanced 19 cents, or 5.4 percent, to $3.69, from the regular close of $3.50.
http://finance.yahoo.com/news/...-4Q-apf-2297286264.html?x=0&.v=2  

   Antwort einfügen - nach oben

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
Aramco (Saudi-Aramco)A2PVHD
Daimler AG710000
Deutsche Bank AG514000
EVOTEC SE566480
NEL ASAA0B733
K+S AGKSAG88
Microsoft Corp.870747
Apple Inc.865985
BVB (Borussia Dortmund)549309
Varta AGA0TGJ5
BASFBASF11
Amazon906866
Ballard Power Inc.A0RENB
Deutsche Telekom AG555750